BioSpace News Archive

Zealand Pharma A/S a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced financial results for the first half of 2022 and provided a corporate update.

A new study published in The Lancet Neurology demonstrates the ability of two blood-based biomarkers to predict how someone will recover from traumatic brain injury (TBI).

Asklepios BioPharmaceutical , Inc. is adding two industry veterans to advance clinical operations and lead corporate communications.

SURE Retractors Inc., a medical device company that has developed a range of industry-disruptive retractors for spinal surgery, announced that Max Reinhardt has been elected to the company’s board of directors, effective immediately.

Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“Izotropic” or the “Company”), a MedTech company commercializing IzoView, an advanced three-dimensional computed tomography (3D CT) breast imaging platform for the more accurate detection and diagnosis of breast cancer, is pleased to report the Company has successfully relocated IzoView and associated components and completed the transition of all major medical device engineering and product development operations to California.

GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company’s proprietary natural killer (NK) cell engager, TriKE® platform, today announced second quarter fiscal 2022 results for the period ended June 30, 2022.

Paige, a global leader in clinical AI applications for pathology, today announced it will partner with Sonora Quest Laboratories, the local market leader in clinical diagnostics in the state of Arizona, to implement a fully digital pathology workflow at its laboratories.

On August 4th, monkeypox (MPV) was declared a national health emergency after reported cases in the US rose in one month by approximately 900%.

Scanslated, Inc., a radiologist-led healthcare technology company, today announced that it has partnered with Duke Health to deliver its patient-centered, interactive radiology reporting service to patients at Duke’s three hospitals and 14 outpatient imaging locations servicing nearly two million patients per year.

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today announced the following.